scholarly journals Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin

2013 ◽  
Vol 38 (1) ◽  
pp. 16-27 ◽  
Author(s):  
S. C. Gordon ◽  
E. M. Yoshida ◽  
E. J. Lawitz ◽  
B. R. Bacon ◽  
M. S. Sulkowski ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Genotype 1 ◽  
Dosing Regimen ◽  
Peginterferon Alfa

scholarly journals A Lower Serum Gamma-Glutamyltransferase Level Does Not Predict a Sustained Virological Response in Patients with Chronic Hepatitis C Genotype 1

Gut and Liver ◽  
2013 ◽  
Vol 7 (1) ◽  
pp. 74-81 ◽  
Author(s):  
Fatih Güzelbulut ◽  
Mesut Sezikli ◽  
Züleyha Akkan Çetinkaya ◽  
Selvinaz Özkara ◽  
Can Gönen ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Genotype 1 ◽  
Lower Serum ◽  
Gamma Glutamyltransferase

scholarly journals Impact of Hepatitis B Exposure on Sustained Virological Response Rates of Highly Viremic Chronic Hepatitis C Patients

2009 ◽  
Vol 2009 ◽  
pp. 1-5
Author(s):  
Ioannis S. Elefsiniotis ◽  
Christos Pavlidis ◽  
Elena Vezali ◽  
Theodoros Mariolis-Sapsakos ◽  
Sotirios Koutsounas ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Genotype 1 ◽  
Treatment Naïve ◽  
The Impact

Aim. To evaluate the impact of hepatitis B core antibody (anti-HBc) seropositivity in sustained virological response (SVR) rates in treatment-naïve, chronic hepatitis C (CHC) patients with high pretreatment viral load (>800000 IU/mL).Methods. 185 consecutive CHC patients (14.4% cirrhotics, 70.2% prior intravenous drug users) treated with pegylated interferon-a2b plus ribavirin, for 24 or 48 weeks based on viral genotype, were retrospectively analyzed. SVR was confirmed by undetectable serum HCV-RNA six months after the end of treatment schedule.Results. Thirty percent of CHC/HBsAg-negative patients were anti-HBc-positive. Anti-HBc positivity was more prevalent in cirrhotic, compared to noncirrhotic patients (76.9% versus 19.5%,P<.05). Serum HBV-DNA was detected in the minority of anti-HBc-positive patients (1.97%). Overall, 62.1% of patients exhibited SVR, while 28.6% did not; 71.4% of non-SVRs were infected with genotype 1. In the univariate analysis, the anti-HBc positivity was negatively associated with treatment outcome (P=.065). In the multivariate model, only the advanced stage of liver disease (P=.015) and genotype-1 HCV infection (P=.003), but not anti-HBc-status (P=.726), proved to be independent predictors of non-SVR.Conclusion. Serum anti-HBc positivity does not affect the SVR rates in treatment-naïve CHC patients with high pretreatment viral load, receiving the currently approved combination treatment.

Sign in / Sign up

Export Citation Format

Share Document